Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 13vPnC in Indian Children
NCT03777865Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoints: Percentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination, Percentage of Participants Reporting Systemic Events by Severity Within 7 Days After Vaccination and 1 more. Started Dec 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03777865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777865.